• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

PD-L1 表达与亚洲和西方胃癌患者的总生存期。

PD-L1 expression and overall survival in Asian and western patients with gastric cancer.

机构信息

Yonsei Cancer Center, Yonsei University Health System, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.

Songdang Institute for Cancer Research, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.

出版信息

Future Oncol. 2022 Jul;18(21):2623-2634. doi: 10.2217/fon-2022-0103. Epub 2022 May 26.

DOI:10.2217/fon-2022-0103
PMID:35616013
Abstract

Data are limited on PD-L1 expression and its association with overall survival (OS) in gastric cancer (GC) patients receiving routine care in different regions. In a retrospective study, PD-L1 expression was assayed using the 22C3 pharmDx on GC tumor samples collected between 2003 and 2017 at South Korean and US cancer centers. PD-L1 positivity was defined as combined positive score (CPS) ≥1. The relationship between PD-L1 and OS was analyzed. Of 574 GC tumor samples, 67.4% were CPS ≥1 (68.7% in Korean and 65.7% in US patients). PD-L1 expression was not associated with OS (adjusted hazard ratio: 0.94; 95% CI: 0.75-1.17). PD-L1 prevalence and its association with OS was similar between South Korean and US GC patients.

摘要

关于在不同地区接受常规治疗的胃癌(GC)患者的 PD-L1 表达及其与总生存期(OS)的关系,数据有限。在一项回顾性研究中,使用 22C3 pharmDx 在 2003 年至 2017 年间于韩国和美国癌症中心收集的 GC 肿瘤样本中检测了 PD-L1 表达。PD-L1 阳性定义为联合阳性评分(CPS)≥1。分析了 PD-L1 与 OS 的关系。在 574 例 GC 肿瘤样本中,67.4%的 CPS≥1(韩国患者为 68.7%,美国患者为 65.7%)。PD-L1 表达与 OS 无关(调整后的危险比:0.94;95%CI:0.75-1.17)。韩国和美国 GC 患者的 PD-L1 患病率及其与 OS 的关系相似。

相似文献

1
PD-L1 expression and overall survival in Asian and western patients with gastric cancer.PD-L1 表达与亚洲和西方胃癌患者的总生存期。
Future Oncol. 2022 Jul;18(21):2623-2634. doi: 10.2217/fon-2022-0103. Epub 2022 May 26.
2
High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features.胃癌(GC)患者中 PD-L1 的高表达及其与分子特征的相关性。
Pathol Res Pract. 2020 Apr;216(4):152881. doi: 10.1016/j.prp.2020.152881. Epub 2020 Feb 13.
3
Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer.双免疫组化染色检测程序性死亡配体-1 表达的联合阳性评分和肿瘤比例评分对晚期胃癌患者预后的影响。
Gastric Cancer. 2020 Jan;23(1):95-104. doi: 10.1007/s10120-019-00999-9. Epub 2019 Aug 26.
4
Programmed death-ligand 1 expression and overall survival in Thai patients with gastric cancer.程序性死亡配体 1 表达与胃癌泰国患者的总生存期。
Sci Rep. 2023 May 4;13(1):7241. doi: 10.1038/s41598-023-34434-y.
5
PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28-8 pharmDx assays for responses to immunotherapy.PD-L1 在胃癌中的表达:22C3 和 28-8 pharmDx 检测试剂用于免疫治疗应答的可互换性。
Mod Pathol. 2021 Sep;34(9):1719-1727. doi: 10.1038/s41379-021-00823-9. Epub 2021 May 17.
6
Scoring systems for PD-L1 expression and their prognostic impact in patients with resectable gastric cancer.用于可切除胃癌患者 PD-L1 表达的评分系统及其预后影响。
Virchows Arch. 2021 Jun;478(6):1039-1048. doi: 10.1007/s00428-020-02956-9. Epub 2020 Oct 24.
7
Prognostic significance of T-cell-inflamed gene expression profile and PD-L1 expression in patients with esophageal cancer.T 细胞炎症基因表达谱和 PD-L1 表达对食管癌患者预后的意义。
Cancer Med. 2021 Dec;10(23):8365-8376. doi: 10.1002/cam4.4333. Epub 2021 Oct 24.
8
Identification of as a Gastric Fungus Associated with PD-L1 Expression and Overall Survival of Patients with Gastric Cancer.鉴定为与 PD-L1 表达和胃癌患者总生存期相关的胃真菌。
J Immunol Res. 2022 Nov 9;2022:2430759. doi: 10.1155/2022/2430759. eCollection 2022.
9
PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs.采用具有临床相关界值的 22C3 PharmDx 和 SP263 检测试剂盒的联合阳性评分对胃癌进行 PD-L1 检测。
Cancer Res Treat. 2020 Jul;52(3):661-670. doi: 10.4143/crt.2019.718. Epub 2020 Jan 10.
10
Discordant PD-L1 results between 28-8 and 22C3 assays are associated with outcomes of gastric cancer patients treated with nivolumab plus chemotherapy.28-8 与 22C3 检测法检测 PD-L1 结果不一致与纳武利尤单抗联合化疗治疗的胃癌患者的结局相关。
Gastric Cancer. 2024 Jul;27(4):819-826. doi: 10.1007/s10120-024-01500-x. Epub 2024 Apr 22.

引用本文的文献

1
Immune checkpoint inhibitors plus chemotherapy in the first-line treatment of young unresectable gastric cancer patients: a multicentre real-world study.免疫检查点抑制剂联合化疗用于年轻不可切除胃癌患者的一线治疗:一项多中心真实世界研究
Front Oncol. 2025 Apr 11;15:1476402. doi: 10.3389/fonc.2025.1476402. eCollection 2025.
2
Prognostic value of PD‑L1 expression and CD68 macrophages in tumor nest of patients with primary gastric cancer.原发性胃癌患者肿瘤巢中PD-L1表达及CD68巨噬细胞的预后价值
Oncol Lett. 2023 Nov 15;27(1):20. doi: 10.3892/ol.2023.14153. eCollection 2024 Jan.
3
Association of PD-L1 Expression with Clinicopathologic Characters in Gastric Cancer: A Comprehensive Meta-analysis.
PD-L1 表达与胃癌临床病理特征的相关性:一项综合荟萃分析。
Curr Med Chem. 2024;31(21):3198-3216. doi: 10.2174/0109298673263784230922060257.
4
Systemic inflammatory biomarkers as prognostic tools in patients with gastroesophageal adenocarcinoma.系统性炎症生物标志物作为胃食管腺癌患者的预后工具。
J Cancer Res Clin Oncol. 2023 Dec;149(19):17081-17091. doi: 10.1007/s00432-023-05424-4. Epub 2023 Sep 26.